| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag at at 5μg/ml (100μl/well) on the plate can bind HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS, 100mM L-arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 Antibody, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human, His Tag with the EC50 of 9.0 ng/ml determined by ELISA.
The purity of HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
| Synonyms |
MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
